MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MORAN, J. F.
Right arrow Articles by TRIGGLE, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MORAN, J. F.
Right arrow Articles by TRIGGLE, D. J.

Molecular Pharmacology, Vol 3, 15-27, Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics

Studies on the Noradrenaline agr-Receptor

I. Techniques of Receptor Isolation. The Distribution and Specificity of Action of N-(2-Bromoethyl)-N-ethyl-1-naphthylmethylamine, a Competitive Antagonist of Noradrenaline

J. F. MORAN 1, M. MAY 1, H. KIMELBERG 1, and D. J. TRIGGLE 1

1 Theoretical Biology Unit, School of Pharmacy, State University of New York at Buffalo, Buffalo, New York 14214

Studies have been made of the potential usefulness of adrenergic blocking 2-halogenoethylamines for labeling time agr-receptor. The uptake of 3H-labeled N-(2-bromoethyl)-N-ethyl-N-1-naphthylmethylamine (3H-SY.28) by rabbit vas deferens was shown to be nonspecific and the 2-halogenoethylamine apparently showed little specificity for the agr-receptor. In an attempt to obtain greater specificity, rabbit aorta and vas deferens were pretreated with N,N-dimethyl-2-bromo-2-phenylethylamine, a short-lasting irreversible agr-receptor antagonist, prior to treatment with 3H-SY.28. Tissues pretreated with the short-lasting antagonist should take up less 3H-SY.28 and the difference between this uptake and that of controls should reflect the concentration of agr-receptor material. However, this treatment did not afford any significant protection against the uptake of 3H-SY.28. The possible protective effects of various amines against labeling by 3H-SY.28 were also investigated: no correlation could be found between the protective ability of these amines and their "direct" or "indirect" sympathomimetic activities. An investigation was also made of the finding that trypsin can reverse the blockade of 3H-SY.28. It was concluded that the recovery of response following trypsin is probably unrelated to agr-receptor regeneration.

The distribution of 3H-SY.28 and its corresponding alcohol was studied in rats. Our results suggest that the prolonged tissue retention of radioactivity following 3H-SY.28 is probably due to the high binding capacities of tissues for 3H-SY.28 alcohol rather than to the presence of high concentrations of covalently bound 3H-SY.28.

Note:
ACKNOWLEDGMENTS The authors wish to thank Miss Marlene Calderone for her technical assistance. This work was supported by Grant GM 11603 from the United States Public Health Service.

Submitted on July 14, 1966







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics